Objective： This study aimed to investigate, for the first time, the expression of circulating miRNAs （microRNAs） related to lipoprotein metabolism in patients with HF （heart failure）. Medlods： Twenty patients wi...Objective： This study aimed to investigate, for the first time, the expression of circulating miRNAs （microRNAs） related to lipoprotein metabolism in patients with HF （heart failure）. Medlods： Twenty patients with HF and 10 controls without HF were included. BNP （brain natxiuretic peptide）, a marker of HF severity, plasma lipid parameters and the expression of circulating miRNAs were determined. Key findings： Total, LDL-, non-HDL- and HDL-cholesterol, txiglycerides, and apo A-I did not differ between both groups, but apo B was lower in the HF group compared to controls （p = 0.007）. In respect to miRNAs, miR-33a, miR-144, miR-125, miR-30c, miR-122, miR-26a, miR-185, miR-758 and miR-106b were higher, from ten- to 25-fold, and miR-10b was lower about 4-fold, in HF group compared to controls. In HF patients a negative correlation between miR-26a and BNP, the marker of disease severity, was found （r = -0.552; p = 0.041）. Conclusions： Plasma levels of miRNAs involved in HDL and LDL metabolism regulation were strikingly changed in HF patients. The negative correlation between miR-26a and BNP values may suggest the possibility of the rise of a novel biomarker or therapeutic target in HF.展开更多
文摘Objective： This study aimed to investigate, for the first time, the expression of circulating miRNAs （microRNAs） related to lipoprotein metabolism in patients with HF （heart failure）. Medlods： Twenty patients with HF and 10 controls without HF were included. BNP （brain natxiuretic peptide）, a marker of HF severity, plasma lipid parameters and the expression of circulating miRNAs were determined. Key findings： Total, LDL-, non-HDL- and HDL-cholesterol, txiglycerides, and apo A-I did not differ between both groups, but apo B was lower in the HF group compared to controls （p = 0.007）. In respect to miRNAs, miR-33a, miR-144, miR-125, miR-30c, miR-122, miR-26a, miR-185, miR-758 and miR-106b were higher, from ten- to 25-fold, and miR-10b was lower about 4-fold, in HF group compared to controls. In HF patients a negative correlation between miR-26a and BNP, the marker of disease severity, was found （r = -0.552; p = 0.041）. Conclusions： Plasma levels of miRNAs involved in HDL and LDL metabolism regulation were strikingly changed in HF patients. The negative correlation between miR-26a and BNP values may suggest the possibility of the rise of a novel biomarker or therapeutic target in HF.
